特治星(哌拉西林/他佐巴坦)在腹腔内感染中的应用(3)
7. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996;51(1):99-136
8. Bryson HM, Brogden RN. Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential . Drugs 1994; 47(3): 506-35
9. Vogel F, Naber KG, Wacha H, and the Expert Group of the Paul-Ehrlich-Society for Chemotherapy, et al. Pareterale antibiotika bei erwachsenen. Chemotherapie J 1999; 3-49
10. Johnson CC, Baldessare J, Levinson ME. Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin Infect Dis 1997; 24; 1035-47
11. Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg 1996; 222:10-8
12. Focht J, Nosner K. Empfindlichkeitsspektrum und anderen antibiotika. Krankenhauspharmazic 1997; 11: 531-4
13. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tzcobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-72
14. Niinikoski J, Tapani H, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993; 176;255-61
15. Eklund AE, Nord CE, Brismar B, et al. A randomized muticenter trial of piperacillin.tazobactam versus imipenem/cilastartin in the treatment of severe intra-abdominal infections. J Anti-microb Chemother 1993; 31 Suppl. A: 79-85
16. Jhee SS, Gill MA, Yellin AE, et al. Pharmakooekonomische untersuchung zum vergleich von piperacillin/tazobactam und imipenem/cilastatin bei der behandlung von patienten mit intraabdominellen infektionen. Clin Ther 1995; 17: 126-35, 百拇医药(李东华)
8. Bryson HM, Brogden RN. Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential . Drugs 1994; 47(3): 506-35
9. Vogel F, Naber KG, Wacha H, and the Expert Group of the Paul-Ehrlich-Society for Chemotherapy, et al. Pareterale antibiotika bei erwachsenen. Chemotherapie J 1999; 3-49
10. Johnson CC, Baldessare J, Levinson ME. Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin Infect Dis 1997; 24; 1035-47
11. Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg 1996; 222:10-8
12. Focht J, Nosner K. Empfindlichkeitsspektrum und anderen antibiotika. Krankenhauspharmazic 1997; 11: 531-4
13. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tzcobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-72
14. Niinikoski J, Tapani H, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993; 176;255-61
15. Eklund AE, Nord CE, Brismar B, et al. A randomized muticenter trial of piperacillin.tazobactam versus imipenem/cilastartin in the treatment of severe intra-abdominal infections. J Anti-microb Chemother 1993; 31 Suppl. A: 79-85
16. Jhee SS, Gill MA, Yellin AE, et al. Pharmakooekonomische untersuchung zum vergleich von piperacillin/tazobactam und imipenem/cilastatin bei der behandlung von patienten mit intraabdominellen infektionen. Clin Ther 1995; 17: 126-35, 百拇医药(李东华)